Perrigo Company plc Receives a Sell from RBC Capital

By Ryan Adsit

In a report released yesterday, Randall Stanicky from RBC Capital reiterated a Sell rating on Perrigo Company plc (NYSE: PRGO), with a price target of $64. The company’s shares opened today at $89.01.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -11.8% and a 26.3% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Perrigo Company plc has an analyst consensus of Moderate Buy, with a price target consensus of $83.86.

Based on Perrigo Company plc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $1.24 billion and GAAP net loss of $69.6 million. In comparison, last year the company earned revenue of $1.34 billion and had a GAAP net loss of $534 million.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.